siHSP47-NP - PDX Pharmaceuticals
Latest Information Update: 28 Jul 2023
Price :
$50 *
At a glance
- Originator PDX Pharmaceuticals
- Class Skin disorder therapies; Small interfering RNA
- Mechanism of Action HSP47 heat shock protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Scleroderma
Most Recent Events
- 27 Jun 2023 Pharmacodynamics data from preclinical trial in Scleroderma released by Pharmaceuticals (PDX Pharmaceuticals pipeline, June 2023)
- 23 Jun 2023 PDX Pharmaceuticals has patent protection for Pdx-NPTM technology in USA(Company website - PDX Pharmaceuticals)
- 23 Jun 2023 Preclinical trials in Scleroderma in USA (Parenteral) (PDX Pharmaceuticals pipeline, June 2023)